Clorazepate Dipotassium

CHEMBL2096631 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

408.9 g/mol

LogP

—

Phase

4

A benzodiazepine prodrug that is converted to active desmethyldiazepam in the stomach, providing anxiolytic, anticonvulsant, and sedative effects. It is used for anxiety disorders, alcohol withdrawal, and as an adjunct in partial seizure management.

Masse moléculaire

408,9200 g/mol

TPSA

82,60 Å²

Aires thérapeutiques

Migraine Lymphoma

Mécanisme d'action

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C([O-])C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O.[K+].[K+].[OH-]

InChI

InChI=1S/C16H11ClN2O3.2K.H2O/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12;;;/h1-8,14H,(H,18,20)(H,21,22);;;1H2/q;2*+1;/p-2

Molecular Formula

C16H11ClK2N2O4

HBD / HBA

2 / 5

Liaisons Rotatives

1

Atomes Lourds

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A benzodiazepine prodrug that is converted to active desmethyldiazepam in the stomach, providing anxiolytic, anticonvulsant, and sedative effects. It is used for anxiety disorders, alcohol withdrawal, and as an adjunct in partial seizure management.

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Yes, Clorazepate Dipotassium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2096631. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 167305. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Clorazepate Dipotassium sur PillFYI

Structure

Données Clés

Formule: C16H11ClK2N2O4

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.